Related Experiment Video
Updated: Sep 9, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
Bezlotoxumab as Treatment for Recurrent/Chronic Clostridioides difficile Infection in Pediatric Stem Cell Transplant
Aaron E Fan1, Shaikha Alqahtani2, Natalie Dailey Garnes3
1Division of Pediatrics, Pediatric Hematology/Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
None:
Clostridioides difficile infection (CDI) represents a significant health risk to pediatric stem cell transplant (SCT) patients. In these patients, recurrent CDI is common, requiring prolonged antibiotic usage and increased hospitalization. Bezlotoxumab, a monoclonal antibody that targets the toxin responsible for CDI, has demonstrated efficacy in adult studies and was recommended for the prevention of recurrent CDI in the adult population. However, the safety and efficacy of bezlotoxumab in pediatric SCT patients have not been extensively described. Moreover, the drug was discontinued in January 2025 for reasons unknown. Here, we describe a series of cases where bezlotoxumab was used in conjunction with antibiotic therapy to effectively treat recurrent CDI in pediatric SCT patients. Bezlotoxumab was not associated with increased adverse events, did not impact management of graft-versus-host disease, and was safe to use in pediatric patients in the peri-transplantation period.
More Related Videos
09:12A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
Published on: June 15, 2018
05:41Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...